Validation timeline overruns delaying SAP EWM go-live
\nIQ \/ OQ \/ PQ execution cycles consuming months of resource time
\nRising consultant costs due to manual documentation overhead
\nRegulatory compliance gaps under pharmaceutical industry standards increasing audit risk
\nURS and Functional Specification sign-off cycles causing project bottlenecks
\nValidation Master Plan milestones missed repeatedly
\nQA team bandwidth exhausted on repetitive manual test documentation<\/p>\n
Woburn, Massachusetts. A mid-sized pharmaceutical manufacturer \u2014 producing serialised, regulated medicines for distribution across the United States and Europe.<\/p>\n
They had invested heavily in SAP EWM. The system was capable, configured and ready. The warehouse team was trained. Leadership had signed off on the go-live roadmap.<\/p>\n
Then the GxP validation cycle began.<\/p>\n
And everything slowed down.<\/p>\n
The QA team was buried in documentation. Every IQ, OQ and PQ protocol needed to be written from scratch, reviewed, approved, executed and then documented all over again. The Validation Master Plan had milestones that kept moving forward on paper \u2014 but never seemed to get closer in reality.<\/p>\n
Three months into the CSV validation pharmaceutical process, the project manager pulled up the tracker in a Monday morning meeting and said nothing for a moment. Then \u2014<\/p>\n
“We are four months behind and we have not even started OQ execution.”<\/p>\n
Nobody in that room had a good answer.<\/p>\n
Over $60,000 monthly (as reported by the client) in external validation consultant fees \u2014 specialists brought in to write protocols, review documents and manage test execution that had no end in sight
\nGo-live date slipped three times \u2014 from Q2 to Q3 to Q4 \u2014 each slip carrying its own cascade of rescheduled training, delayed warehouse transitions and renegotiated vendor contracts
\nQA team logging 60 to 70 hour weeks \u2014 not doing quality work, but chasing document approvals, version control issues and manual test scripts that needed constant updating every time a configuration changed
\nRegulatory audit readiness was deteriorating \u2014 electronic record keeping and approval workflows were not consistently maintained across the full validation lifecycle, creating exposure under pharmaceutical computerised system validation regulations governing data integrity and electronic records
\nURS sign-off cycles were taking three to four weeks per iteration \u2014 every change request triggering a full review loop that consumed everyone’s calendar
\nThe compliance director had stopped giving go-live estimates to senior leadership entirely \u2014 she simply did not have a number she could stand behind<\/p>\n
This was not a technology failure. The SAP EWM system was working perfectly.<\/p>\n
The bottleneck was the validation process itself \u2014 slow, manual, repetitive and completely disconnected from the pace the business needed to move at.<\/p>\n
By month five, the VP of Operations had seen enough.<\/p>\n
A colleague in the industry \u2014 a supply chain director at another Massachusetts pharma firm \u2014 mentioned SCM Champs in passing. Not as a formal recommendation. Just a quiet word over coffee \u2014<\/p>\n
“They brought pre-built validation packages for our SAP EWM go-live validation. Our CSV timeline improved significantly. You should call them.”<\/p>\n
The Woburn team had been at it for five months with no end in sight.<\/p>\n
The VP sent an email to SCM Champs that same evening. The reply came the next morning. A scoping call was set for the following day \u2014 no lengthy intake forms, no generic capability decks. Just a direct conversation with people who had clearly done this before.<\/p>\n
When the SCM Champs validation team reviewed the project, the picture became clear very quickly. And honestly \u2014 what they found was not unusual. They had seen it in almost every manual GxP validation SAP EWM engagement across the industry.<\/p>\n
Finding 1 \u2014 Everything was being built from scratch<\/strong> Finding 2 \u2014 No traceability matrix was maintained in real time<\/strong> Finding 3 \u2014 Validation phases were running sequentially with no risk-based planning<\/strong> Finding 4 \u2014 Test management was fragmented across spreadsheets and emails<\/strong> Finding 5 \u2014 Change control was triggering full re-validation loops unnecessarily<\/strong> Step 1 \u2014 Deployed Pre-Built GxP Validation Package for SAP EWM<\/strong><\/p>\n SCM Champs arrived with a complete library of ready-to-use, pharma-grade validation documentation \u2014 purpose built for SAP EWM environments operating under GxP requirements.<\/p>\n This included a fully structured Validation Master Plan, ready-to-execute IQ OQ and PQ protocols covering the complete scope of SAP EWM warehouse processes, and URS and Functional Specification templates mapped directly to SAP EWM standard functionality.<\/p>\n To be clear about what each phase covers \u2014 IQ confirmed that SAP EWM was installed and configured correctly against vendor specifications. OQ verified that each system function performed correctly against URS and Functional Specification requirements across all core EWM processes including Goods Receipt, Putaway, Stock Transfers, Pick and Pack, Goods Issue, Batch and Serial number management, Handling Unit management and ERP to EWM integration. PQ validated that end-to-end business processes performed consistently under realistic operating conditions.<\/p>\n A live Requirements Traceability Matrix was maintained throughout the entire engagement \u2014 every requirement linked to its corresponding test evidence from day one.<\/p>\n What previously consumed weeks of consultant authoring time became a focused configuration and review exercise. Manual effort was significantly reduced from day one.<\/p>\n Step 2 \u2014 Applied Risk-Based Validation Strategy Aligned to GAMP 5<\/strong><\/p>\n Not every process in SAP EWM carries the same compliance weight. SCM Champs applied a structured risk-based validation strategy grounded in GAMP 5 guidelines \u2014 formally categorising each system function by its impact on product quality, patient safety and data integrity.<\/p>\n SAP EWM as a configured commercial off-the-shelf system falls under GAMP 5 Software Category 4 \u2014 requiring a validation approach proportionate to the configuration complexity and business risk of each process area. Processes at the highest risk level \u2014 serialisation, batch management, goods issue to production, QM integration \u2014 received complete IQ OQ PQ coverage with full documentation. Lower-risk administrative and reporting functions were handled through documented risk assessments rather than full test cycles.<\/p>\n This risk-based approach is not a shortcut. It is the correct methodology under GAMP 5. It removed weeks of unnecessary execution from the project timeline without any compromise to compliance standing.<\/p>\n Step 3 \u2014 Structured Test Management via SAP Solution Manager<\/strong><\/p>\n SAP Solution Manager was configured as the central test management platform for the validation programme \u2014 providing structured test case management, documentation tracking and sign-off workflows directly within the SAP landscape. Test cases were loaded, assigned and executed within Solution Manager. Defects were raised, tracked and resolved in the same environment \u2014 creating a consistent, traceable electronic record across the full validation lifecycle. Clean. Auditable. Inspection ready.<\/p>\n Step 4 \u2014 Introduced Controlled Phase Overlap Based on Risk Assessment<\/strong><\/p>\n IQ, OQ and PQ are sequential validation phases by design \u2014 each serving a distinct and specific purpose in the validation lifecycle. Compressing or merging these phases without formal justification is a compliance risk, not an efficiency gain. That is something every experienced validation practitioner knows.<\/p>\n What SCM Champs introduced was a formally documented controlled overlap approach \u2014 applied only where the risk assessment specifically supported it. Where IQ sign-off on one process area was complete and approved, OQ scripting and preparation for that area began in parallel with IQ execution on remaining areas. PQ scoping commenced once sufficient OQ evidence was available to support it.<\/p>\n Every overlap decision was documented, risk-justified and approved. Nothing was rushed. The result was a meaningful reduction in overall timeline without a single compromise to validation integrity.<\/p>\n Step 5 \u2014 Established Risk-Based Change Control Process<\/strong><\/p>\n A structured change impact assessment process was introduced \u2014 built around the client’s existing change control procedures. Every configuration change was now evaluated against a defined risk framework before any re-validation activity was triggered.<\/p>\n Low and medium risk changes \u2014 those with no direct impact on validated GxP functions \u2014 were resolved through documented impact assessments. Only changes directly affecting high-risk process areas required formal re-testing with updated test evidence. The cycle of disproportionate re-validation that had been consuming weeks of project time was brought under control.<\/p>\n Step 6 \u2014 Full Validation Lifecycle Review and Regulatory Readiness Assessment<\/strong><\/p>\n Before closing the validation lifecycle, SCM Champs completed a thorough end-to-end review of all validation deliverables \u2014<\/p>\n Electronic records completeness and accuracy across all validated system functions The client’s compliance team completed their internal review of the full validation package. Audit readiness was confirmed and the team proceeded to go-live with full confidence.<\/p>\n The difference was visible from the first weeks of the engagement.<\/p>\n CSV timeline improvement of approximately 40% (as reported by the client) compared to the original projected duration The VP of Operations sent a short note to the SCM Champs team on go-live day \u2014<\/p>\n “Five months of going nowhere. Working with your team changed that. I wish we had made this call sooner.”<\/p>\n That note still sits in the SCM Champs project archive.<\/p>\n
\nThere were no pre-built validation templates in place. Every IQ, OQ and PQ protocol was being written from zero \u2014 by consultants billing by the hour. Every test script was manually authored for this specific project. Nothing was reusable. Nothing was standardised. Every document looked different from the last.<\/p>\n
\nThe Requirements Traceability Matrix \u2014 connecting URS requirements through Functional Specifications, Design Specifications and live test evidence \u2014 was being updated manually in spreadsheets after the fact. When configurations changed, the traceability matrix was often weeks behind. This was opening serious gaps in the documentation trail \u2014 creating direct exposure under pharmaceutical computerised system validation regulations governing data integrity and electronic records.<\/p>\n
\nEvery validation phase was waiting for the previous one to fully close before the next one began \u2014 without any formal risk assessment to determine where controlled overlap could be safely applied. IQ completion was waiting on final sign-offs. OQ could not start until IQ was formally approved. PQ was not even being scoped until OQ was done. In a project of this size, this approach was adding months of pure waiting time to the timeline.<\/p>\n
\nThe team was managing test execution through shared spreadsheets and email chains. SAP Solution Manager \u2014 which supports structured test management, documentation tracking and sign-off workflows directly within the SAP landscape \u2014 was available but completely unused. Every test result was being manually transcribed. Every defect was being tracked in a separate log. The audit trail was fragmented across multiple tools and inboxes.<\/p>\n
\nEvery minor configuration change \u2014 even low-risk adjustments \u2014 was being routed through a full change control and re-validation cycle. There was no risk-based framework applied to determine which changes genuinely required re-testing and which could be resolved with a documented impact assessment. This alone was responsible for significant delay across the project timeline.<\/p>\nWhat SCM Champs Delivered \u2014 Step by Step<\/h2>\n
\nAudit trail integrity maintained throughout the full validation lifecycle
\nDigital approval workflows confirmed across all sign-off points
\nTraceability matrix verified from URS through to final test evidence \u2014 no gaps
\nValidation Summary Report authored, reviewed and approved<\/p>\nWhat Changed \u2014 Business Impact After Delivery<\/h2>\n
\nExternal consultant costs reduced significantly \u2014 ready-to-use templates removed the bulk of manual authoring hours from the project
\nGo-live achieved in Q4 as originally planned \u2014 the third rescheduled date finally held
\nRegulatory audit readiness strengthened \u2014 the full validation package was inspection-ready at go-live with no open documentation gaps
\nQA team manual effort reduced substantially \u2014 the unsustainable workload that had built up over months began easing within the first three weeks
\nFull Requirements Traceability Matrix delivered \u2014 clean, complete and traceable from URS through to final test evidence
\nThe compliance director finally had a position she could take to senior leadership with confidence<\/p>\nWhy SCM Champs<\/h2>\n